REG - ValiRx PLC - Shareholder Requisition Notice

ValiRxAnnouncement

04/03/2024 18:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240304:nRSD5366Fa&default-theme=true

RNS Number : 5366F  ValiRx PLC  04 March 2024

4 March 2024

VALIRX PLC

("ValiRx" or the "Company")

Shareholder Requisition Notice

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health, announces that it has
received a requisition from shareholders representing over 7% of the Company's
voting rights to convene a General Meeting ("GM") of the Company (the
"Requisition") under section 303 of the Companies Act 2006 (the "Act"). The
Requisition requests for the following Ordinary Resolutions to be proposed at
the General Meeting:

 

1.     That Martin Lampshire be removed from the board of directors of the
Company with immediate effect.

2.     That Kevin Cox be removed from the board of directors of the
Company with immediate effect.

3.     That Adrian De Courcey be appointed as a non-executive director of
the Company with immediate effect.

4.     That Benjamin Snipe be appointed as a non-executive director of the
Company with immediate effect.

5.     That Ray Horn be appointed as Board Observer of the Company with
immediate effect.

6.     That, subject to the passing of resolution 2, a) an interim
Chairperson be appointed to the Board of the Company; and b) Shard Capital,
the Company's broker, be requested by the Board to provide at least one
candidate for the permanent role of non-executive Chairperson by 31 May 2024;
if at least one candidate is provided to the Board, the Board may decide to
appoint to the role accordingly, but is not required to; otherwise the Board
is to proceed with recruitment to the role using services of an external
recruitment agency.

7.     That any person appointed as a director of the Company since the
date of the requisition of the general meeting of the Company at which this
resolution is proposed, and who is not one of the persons referred to in the
resolutions numbered 3 and 4 above, be and is hereby removed as a director of
the Company.

 

A further announcement will be made by the Company relating to the calling of
a General Meeting and a Notice of General Meeting and accompanying circular
will posted to shareholders.

 

Pursuant to section 304 of the Companies Act 2006, the Company must post a
notice convening a general meeting within 21 days from the date on which the
requisition was received, and this meeting must be held on a date not more
than 28 days after the date of the notice to shareholders convening the
general meeting.

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR").

 

The Directors of the Company take responsibility for this announcement.

 

For more information, please contact:

 

 ValiRx plc                                        Tel: +44 (0) 2476 796496

                                                   www.valirx.com (http://www.valirx.com)

 Dr Suzanne Dilly, CEO                             Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz
 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray/Jo Turner/Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

Cautionary statement

Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCJIMRTMTIMBAI